Quick Answer
Nasus Pharma Ltd reported Net Income of -$5.86 million for fiscal year 2025.
Nasus Pharma Ltd — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net Income | -$5.86M -282.2% |
-$1.53M -45.8% |
-$1.05M | — |
| Diluted EPS | -$0.72 -227.3% |
-$0.22 -10.0% |
-$0.20 | — |
| Total Assets | $5.00M +597.9% |
$717.0K | — | — |
| Cash and Equivalents | $1.24M +335.6% |
$284.0K +47.2% |
$193.0K | — |
| Stockholders Equity | $2.77M +186.2% |
-$3.21M +15.4% |
-$3.80M -36.3% |
-$2.79M |
| R&D Expense | $2.24M +567.8% |
$335.0K -40.9% |
$567.0K | — |
| Operating Income | -$4.90M -354.9% |
-$1.08M +6.0% |
-$1.15M | — |
- Nasus Pharma Ltd reported Net Income of -$5.86 million for fiscal year 2025.
- Nasus Pharma Ltd showed a decrease of -282.2% in Net Income compared to the prior fiscal year.
- Nasus Pharma Ltd reported Diluted EPS of $0.72 per share (loss) for fiscal year 2025.
- Nasus Pharma Ltd showed a decrease of -227.3% in Diluted EPS compared to the prior fiscal year.
- Nasus Pharma Ltd reported Total Assets of $5.00 million for fiscal year 2025.
- Nasus Pharma Ltd showed an increase of +597.9% in Total Assets compared to the prior fiscal year.
- Nasus Pharma Ltd reported Cash and Equivalents of $1.24 million for fiscal year 2025.
- Nasus Pharma Ltd showed an increase of +335.6% in Cash and Equivalents compared to the prior fiscal year.
- Nasus Pharma Ltd reported Stockholders Equity of $2.77 million for fiscal year 2025.
- Nasus Pharma Ltd showed an increase of +186.2% in Stockholders Equity compared to the prior fiscal year.
- Nasus Pharma Ltd reported R&D Expense of $2.24 million for fiscal year 2025.
- Nasus Pharma Ltd showed an increase of +567.8% in R&D Expense compared to the prior fiscal year.
- Nasus Pharma Ltd reported Operating Income of -$4.90 million for fiscal year 2025.
- Nasus Pharma Ltd showed a decrease of -354.9% in Operating Income compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: